Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial (JACC Heart Failure April 2024)-Article: Contemporary Use and Implications of Beta-Blockers in Patients With HFm

Article: Contemporary Use and Implications of Beta-Blockers in Patients With HFm_The DELIVER TrEF orrial

Pdf Summary

The study explored the use of beta-blockers in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF and HFmrEF) alongside dapagliflozin in the DELIVER trial. Beta-blocker usage was associated with reduced cardiovascular risks in these patients, and dapagliflozin further lowered the risk regardless of beta-blocker use. The study did not find increased adverse outcomes with beta-blockers in HFpEF patients and indicated consistent benefits of dapagliflozin across beta-blocker users and non-users. Concerns about beta-blocker impact on chronotropic response were not supported by the study's results. The combined therapy of dapagliflozin and beta-blockers showed favorable outcomes with similar safety profiles. Overall, the study supports the effectiveness and safety of beta-blockers in managing heart failure, emphasizing their importance in patient care. Future trials are recommended for validation and further exploration of beta-blocker therapy in heart failure patients.

Keywords

beta-blockers

heart failure

HFpEF

HFmrEF

DELIVER trial

dapagliflozin

cardiovascular risks

chronotropic response

combined therapy

patient care